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DA-9701 is a new botanical drug composed of the extracts of Corydalis tuber and Pharbitidis semen, and it is used as an oral
therapy for the treatment of functional dyspepsia in Korea. The inhibitory potentials of DA-9701 and its component herbs,
Corydalis tuber and Pharbitidis semen, on the activities of seven major human cytochrome P450 (CYP) enzymes and four UDP-
glucuronosyltransferase (UGT) enzymes in human liver microsomes were investigated using liquid chromatography-tandem
mass spectrometry. DA-9701 and Corydalis tuber extract slightly inhibited UGT1A1-mediated etoposide glucuronidation, with
50% inhibitory concentration (IC50) values of 188 and 290μg/mL, respectively. DA-9701 inhibited CYP2D6-catalyzed bufuralol
1 -hydroxylation with an inhibition constant (Ki) value of 6.3μg/mL in a noncompetitive manner. Corydalis tuber extract
competitively inhibited CYP2D6-mediated bufuralol 1 -hydroxylation, with a Ki value of 3.7μg/mL, whereas Pharbitidis semen
extractshowednoinhibition.ThevolumeinwhichthedosecouldbedilutedtogenerateanIC50 equivalentconcentration(volume
per dose index) value of DA-9701 for inhibition of CYP2D6 activity was 1.16L/dose, indicating that DA-9701 may not be a potent
CYP2D6 inhibitor. Further clinical studies are warranted to evaluate the in vivo extent of the observed in vitro interactions.
1.Introduction
Functionaldyspepsiaisaverycommonchronicgastrointesti-
nal disorder, with a prevalence of 40% using the more liberal
criteria [1]. Although the etiology and pathogenesis of func-
tional dyspepsia are poorly understood, pathophysiologic
abnormalitiessuchasdelayedgastricemptyingandimpaired
gastric accommodation have been reported in 30–40% of
functional dyspepsia patients [2–5]. Medications used for
the treatment of functional dyspepsia have been developed
basedonthepathophysiologicalmechanismsassociatedwith
functional dyspepsia; those medications include prokinetic
agents,whicharenowrestrictedduetoseriousadverseeﬀects
and failure to conﬁrm their eﬃcacy. Therefore, it is necessary
to develop saferand more eﬀectivedrugsforthetreatmentof
functional dyspepsia.
DA-9701 is a new botanical drug composed of the
extracts of Corydalis tuber from the roots of Corydalis
yanhusuo W. T. Wang and Pharbitidis semen from the seed
of Pharbitis nil Choisy, and it is used as an oral therapy
(Motilitone) for the treatment of functional dyspepsia
(FD) in Republic of Korea since May 2011 [6–8]. Pharbitidis
semen has been used as a folk medicine for its analgesic
eﬀect on abdominal disorders. Corydalis tubers from the
roots of Corydalis yanhusuo W. T. Wang have long been2 Evidence-Based Complementary and Alternative Medicine
used as a herbal drug for their analgesic and antiulcer eﬀects
[9–11]. Corydaline and tetrahydroberberine, isoquinoline
alkaloids of Corydalis tubers, promote gastric emptying and
facilitate gastric accommodation [12, 13]. DA-9701 has been
demonstrated to show strong gastroprokinetic eﬀects and a
safety proﬁle superior to cisapride and mosapride [7, 8]. The
gastroprokinetic eﬀects of DA-9701 might be mediated by
the induction of pacemaker currents in the interstitial cells
of Cajal (ICC) [6]. DA-9701 also has been shown to have
antagonistic eﬀects on the D2 receptor and agonistic eﬀects
on 5-HT4, 5-HT1a, and 5-HT1b receptors [7, 8].
Since botanical drugs share the same drug metaboliz-
ing enzymes, including cytochrome P450 (CYP) enzymes,
UDP-glucuronosyltransferase (UGT) enzymes, and drug
transporters, such as multidrug resistance protein and p-
glycoprotein, with commonly used drugs, the potential for
herb-drug interaction is substantial [14–16]. Several medic-
inal herbs, including Dong quai (Angelica polymorpha),
ginkgo (Ginkgo biloba), ginseng (Panax ginseng), milk thistle
(Silybum marianum), licorice (Glycyrrhiza glabra), St. John’s
wort (Hypericum perforatum), and Woohwangcheongsim-
won have been reported to cause herb-drug interactions
[17–20]. Herb-drug interactions have been identiﬁed with
St. John’s wort that signiﬁcantly involve reduced blood con-
centrations of cyclosporine, digoxin, midazolam, indinavir,
tacrolimus, theophylline, and warfarin [21]. Undoubtedly,
the early identiﬁcation of herb-drug interactions is imper-
ative to prevent potentially dangerous clinical outcomes.
To the best of our knowledge, no previous study has
reported the eﬀects of Corydalis tubers and Pharbitidis
semen, the component herbs of DA-9701, on human CYP
and UGT enzymes. In this study, the eﬀects of DA-9701
and its component herbs, Corydalis tubers and Pharbitidis
semen, on the activities of seven major human CYP enzymes
and four major human UGTs, 1A1, 1A4, 1A9, and 2B7, were
examined using pooled human liver microsomes in order to
evaluate the possibility of drug interactions of DA-9701.
2. Experimental
2.1. Materials and Reagents. Corydaline, palmatine, and
chlorogenic acid were obtained from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan). Acetaminophen, alamethi-
cin, coumarin, diclofenac, etoposide, glucose-6-phosphate,
glucose-6-phosphate dehydrogenase, 7-hydroxycoumarin,
midazolam, β-nicotinamide adenine dinucleotide phos-
phate reduced form (NADPH), phenacetin, propofol,
triﬂuoperazine, and uridine-5-diphosphoglucuronic acid
trisodium salt (UDPGA) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Pooled human liver
microsomes (H161), 13C2, 15N-acetaminophen, bu-furalol,
N-desethylamodiaquine, 1 -hydroxybufuralol, d9-1 -hy-
droxybufuralol maleate, 4-hydroxydiclofenac, 13C6-4-
hydroxydiclofenac, 4-hydroxymephenytoin, d3-4-hydroxy-
mephenytoin, 1 -hydroxymidazolam, and (S)- mephenytoin
were obtained from BD Gentest Co. (Woburn, MA, USA).
Azidothymidine, azidothymidine glucuronide, and propofol
glucuronide were obtained from Toronto Research Center
(Toronto,Canada).Acetonitrileandmethanol(HPLCgrade)
were obtained from Burdick & Jackson Inc. (Muskegon, MI,
USA), and the other chemicals were of the highest quality
available.
2.2. Preparation of DA-9701. DA-9701 is a standardized
extract of Corydalis tuber and Pharbitidis semen which was
prepared as previously reported [8]. Brieﬂy, those dried
herbs were mixed in a speciﬁc ratio (5:1) and extracted
with 50% aqueous ethanol three times at room temperature
for 48h. After ﬁltration, the aqueous ethanol extract was
evaporated under reduced pressure and lyophilized for a
complete removal of the residual solvent to yield brown
powder. Contents of two marker components, corydaline,
an alkaloid, from Corydalis tuber and chlorogenic acid from
Pharbitidis semen in DA-9701, were determined by high
performance liquid chromatography (HPLC) [8].
Corydalis tuber extract and Pharbitidis semen extract
were prepared as previously described [13]. Brieﬂy, dried
Corydalis tuber and Pharbitidis semen were separately
extracted with 50% aqueous ethanol three times at room
temperature for 48h. The solvents were removed under
vacuum. The marker compounds including corydaline from
Corydalis tuber extract and chlorogenic acid from Pharbi-
tidis semen extract were also determined by HPLC [8]. The
two raw materials were purchased in China.
2.3. Inhibitory Eﬀects of DA-9701 and Its Component
H e r b so nS e v e nM a j o rC Y PA c t i v i t i e si nH u m a nL i v e r
Microsomes. Inhibitory potencies (IC50 values) of DA-9701,
Corydalis tuber extract, and Pharbitidis semen extract were
determined using CYP assays in the presence and absence
of DA-9701, Corydalis tuber extract, and Pharbitidis semen
extract using pooled human liver microsomes (H161,
Gentest). Phenacetin O-deethylase, coumarin 7-hydroxylase,
amodiaquine N-deethylase, diclofenac 4-hydroxylase, (S)-
mephenytoin 4-hydroxylase, bufuralol 1 -hydroxylase, and
midazolam 1 -hydroxylase activities were determined as
probe activities for CYP1A2, CYP2A6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, and CYP3A, respectively, using cocktail
incubation and liquid chromatography-tandem mass
spectrometry (LC/MS/MS) [22]. The incubation mixtures
were prepared in a total volume of 200μL as follows: pooled
human liver microsomes (0.25mg/mL), 3.3mM MgCl2,
50mM potassium phosphate buﬀer (pH 7.4), and a cocktail
of probe substrates and various concentrations of DA-
9701, Corydalis tuber extract, or Pharbitidis semen extract
(ﬁnal concentrations of 1–200μg/mL with an acetonitrile
concentration less than 0.5% v/v). The substrates were
used at concentrations approximately equal to their
respective Km values: 50μM phenacetin, 2.5μM coumarin,
2.5μM amodiaquine, 10μM diclofenac, 100μM( S)-
mephenytoin, 5μM bufuralol, and 2.5μM midazolam. After
a 3-min preincubation period at 37◦C, the reactions were
initiated by addition of an NADPH (ﬁnal concentration
of 1.3mM) generating system and incubated for 20min
at 37◦C in a shaking water bath. After incubation, the
reaction was stopped by placement of the tubes on ice andEvidence-Based Complementary and Alternative Medicine 3
addition of 100μL of ice-cold methanol containing internal
standards (13C2, 15N-acetaminophen for acetaminophen
and N-desethylamodiaquine, d5-7-hydroxycoumarin for
7-hydroxycoumarin, 13C6-4-hydroxydiclofenac for 4-
hydroxydiclofenac, d3-4-hydroxy-mephenytoin for 4-
hydroxymephenytoin and 1 -hydroxymidazolam, d9-1 -
hydroxybufuralol for 1 -hydroxybufuralol). The incubation
mixtures were then centrifuged at 13,000 × g for 5min.
All incubations were performed in triplicate, and the mean
values were used. For evaluation of NADPH-dependent
mechanism-based inhibition of CYP activities, various
concentrations of DA-9701, Corydalis tuber extract,
or Pharbitidis semen extract (1–200μg/mL) were pre-
incubated for 30min with human liver microsomes in the
presence of NADPH. The reaction was started by addition of
a cocktail of CYP probe substrates.
All seven metabolites produced from the cocktail incu-
bation of CYP isoform-speciﬁc substrates were simultane-
o u s l yd e t e r m i n e db yL C / M S / M S[ 22]. The system consisted
of a tandem mass spectrometer (TSQ Quantum Access,
ThermoFisher Scientiﬁc, San Jose, CA, USA) coupled with
a Nanospace SI-2 LC system (Tokyo, Japan). Separation
was performed on an Atlantis dC18 column (5μm, 2.1mm
i.d. ×100mm, Waters, MA, USA) using the gradient elution
of a mixture of 5% methanol in 0.1% formic acid (mobile
phase A) and 95% methanol in 0.1% formic acid (mobile
phase B) at a ﬂow rate of 0.25mL/min: 10% mobile phase
B for 1min, 10% to 95% mobile phase B for 1min,
and 95% mobile phase B for 5min. The column and
autosampler temperatures were 50 and 6◦C, respectively.
After 1.5min, the LC eluent was diverted from waste to
the mass spectrometer ﬁtted with the electrospray ionization
( E S I )s o u r c ea n do p e r a t e di np o s i t i v ei o nm o d e .E S Is o u r c e
settings for ionization of the metabolites were as follows:
electrospray voltage, 5.0kV; vaporizer temperature, 420◦C;
capillary temperature 360◦C; sheath gas pressure, 35psi;
auxiliary gas pressure, 10psi. Quantiﬁcation was performed
by selected reaction monitoring (SRM) of the [M+H]
+
ion and the related product ion for each metabolite. SRM
transitions for the metabolites and internal standards are
summarized in our previous paper [22]. Analytical data
were processed using Xcalibur software (Thermo Fisher
Scientiﬁc).
2.4. Inhibitory Eﬀects of DA-9701 and Its Component
Herbs on Four UGT Activities in Human Liver Micro-
somes. The inhibitory potencies (IC50 values) of DA-9701,
Corydalis tuber extract, or Pharbitidis semen extract were
also determined with UGT assays in the presence and
absence of DA-9701, Corydalis tuber extract, or Pharbi-
tidis semen extract using pooled human liver microsomes.
Etoposide glucuronidation, triﬂuoperazine glucuronidation,
propofol glucuronidation, and azidothymidine glucuronida-
tion activities were determined as probe activities for
UGT1A1, UGT1A4, UGT1A9, and UGT2B7, respectively,
using LC/MS/MS [23]. Incubation mixtures were prepared
in a total volume of 100μL as follows: pooled human
liver microsomes (0.2mg/mL for etoposide, triﬂuoperazine,
and azidothymidine; 0.1mg/mL for propofol), 25μg/mL
alamethicin,10mMMgCl2,50mMtri sb uﬀer(pH7.4),each
UGT-isoform speciﬁc probe substrate (200μM etoposide for
UGT1A1,5μMtriﬂuoperazineforUGT1A4,10μMpr opofol
for UGT1A9, or 100μM azidothymidine for UGT2B7),
and various concentrations of DA-9701, Corydalis tuber
extract, or Pharbitidis semen extract (ﬁnal concentrations
of 1–200μg/mL with acetonitrile concentration less than
0.5% v/v). Reactions were initiated by addition of UDPGA
(ﬁnal concentration of 5mM), and incubations were carried
o u ta t3 7 ◦C in a shaking water bath for 30min. Reac-
tions were terminated by addition of 100μL of ice-cold
methanol containing an internal standard (100ng/mL eze-
timibe for etoposide glucuronide and propofol glucuronide;
30ng/mL meloxicam for triﬂuoperazine glucuronide and
azidothymidine glucuronide). The incubation mixtures were
centrifuged at 13,000 × g for 5min, followed by dilution of
40μL of the supernatant with 60μL of water. The aliquot
(5μL) was injected onto LC/MS/MS. All incubations were
performed in duplicate and the mean values were used.
Glucuronides produced from UGT isoform-speciﬁc sub-
strates were, respectively, determined by LC/MS/MS [23].
Separation was performed on an Atlantis dC18 column
(5μm, 2.1mm i.d. ×100mm, Waters, MA, USA) using the
gradientelutionofamixtureof5%methanolin0.1%formic
acid (mobile phase A) and 95% methanol in 0.1% formic
acid (mobile phase B) at a ﬂow rate of 0.25mL/min: 10%
mobile phase B for 2min, 10% to 95% mobile phase B
for 4min. The column and autosampler temperatures were
50 and 6◦C, respectively. After 3.0min, the LC eluent was
diverted from waste to the mass spectrometer ﬁtted with an
ESI source. ESI source settings for ionization of triﬂuoper-
azine glucuronide and azidothymidine glucuronide in pos-
itive ion mode were as follows: electrospray voltage, 5.0kV;
vaporizer temperature, 420◦C; capillary temperature 360◦C;
sheath gas pressure, 35psi; auxiliary gas pressure, 10psi. ESI
source settings for ionization of etoposide glucuronide and
propofol glucuronide in negative ion mode were as follows:
electrospray voltage, −4.0kV; vaporizer temperature, 420◦C;
capillary temperature 360◦C; sheath gas pressure, 35psi;
auxiliary gas pressure, 10psi. Quantiﬁcation was performed
by SRM of the [M+H]
+ ion for triﬂuoperazine glucuronide
and azidothymidine glucuronide or [M −H]
− for etoposide
glucuronide and propofol glucuronide and the related
product ion for each metabolite. SRM transitions for the
metabolites and internal standard are summarized in our
previous paper [23]. Analytical data were processed using
Xcalibur software (Thermo Fisher Scientiﬁc).
2.5. Kinetic Analysis. In order to determine Ki values of DA-
9701, Corydalis tuber extract, and a typical inhibitor quini-
dine for CYP2D6 enzyme, human liver microsomes (0.1mg/
mL) were incubated with various concentrations of 0.5 −
5μM bufuralol, 10mM MgCl2, and various concentrations
of DA-9701, Corydalis tuber extract, or quinidine in 50mM
potassium phosphate buﬀer (pH 7.4) in a total incubation
volume of 200μL. Reactions were initiated by addition of
NADPH (ﬁnal concentration of 1mM) at 37◦C and stopped4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀects of DA-9701, Corydalis tuber extract (CT Ex), and Pharbitidis semen extract (PS Ex) on CYP metabolic activity in pooled
human liver microsomes, H161 using cocktail substrate assay.
CYP activity CYP
IC50, μg/mL (VDI∗∗,L / d o s e )
No preincubation With preincubation∗
DA-9701 CT Ex PS Ex DA-9701 CT Ex PS Ex
Phenacetin O-deethylation 1A2 N.I.∗∗∗ N.I. N.I. N.I. N.I. N.I.
Coumarin 7-hydroxylation 2A6 N.I. N.I. N.I. N.I. N.I. N.I.
Amodiaquine N-deethylation 2C8 N.I. N.I. N.I. N.I. N.I. N.I.
Diclofenac 4-hydroxylation 2C9 N.I. N.I. N.I. N.I. N.I. N.I.
S-mephenytoin 4 -hydroxylation 2C19 N.I. 145.9 N.I. 167.6 (0.18)∗∗ 130.3 N.I.
Bufuralol 1 -hydroxylation 2D6 25.9 (1.16)∗∗ 15.8 N.I. 34.3 (0.88)∗∗ 16.7 N.I.
Midazolam 1 -hydroxylation 3A4 N.I. N.I. N.I. N.I. N.I. N.I.
∗DA-9701, Corydalis tuber extract (CT Ex), and Pharbitidis semen extract (PS Ex) were preincubated for 30 min in the presence of NADPH before the
addition of the substrate. ∗∗VDI: volume per dose index, ∗∗∗N.I.: no inhibition at 200μg/mL of DA-9701. Cocktail substrate concentrations used for the
assessment of IC50 were as follows: 50μM phenacetin, 2.5μM coumarin, 2.5μM amodiaquine, 10μM diclofenac, 100μM( S)-mephenytoin, 5.0μM bufuralol,
and 2.5μM midazolam. The data represent the average of three determinations.
Table 2:Ki valuesfortheinhibitionofCYP2D6-catalyzedbufuralol
1 -hydroxylation activity by DA-9701, Corydalis tuber extract, and
quinidine in pooled human liver microsomes, H161.
Substances Ki Inhibition mode
DA-9701 6.3 μg/mL Noncompetitive
Corydalis tuber extract 3.7 μg/mL Competitive
Quinidine 0.038 μM Noncompetitive
after 15min by placement of the incubation tubes on ice
and addition of 100μL of ice-cold methanol containing an
internal standard (0.5μg/mL d9-1 -hydroxybufuralol). The
incubationmixtureswerecentrifugedat13,000×gfor5min,
and aliquots (5μL) of the supernatants were analyzed by
LC/MS/MS.
2.6. Data Analysis. IC50 values (concentration of inhibitor
causing 50% inhibition of the original enzyme activity) were
calculated using WinNonlin software, a nonlinear regression
analysis program (Pharsight, Mountain View, CA, USA).
Apparent kinetic parameters for inhibitory potential (Ki
values) were estimated from the ﬁtted curves using Enzyme
Kinetics Ver. 1.3 program (Systat Software Inc., San Jose, CA,
USA).
3. Results andDiscussion
The inhibitory eﬀects of DA-9701, Corydalis tuber extract,
and Pharbitidis semen extract on seven major human
CYP isoforms were evaluated using cocktail CYP probe
substrates in human liver microsomes. CYP2D6-catalyzed
bufuralol 1 -hydroxylation activity was inhibited by DA-
9701 and Corydalis tuber extract with IC50 values of
25.9 and 15.8μg/mL, respectively, but not by Pharbi-
tidis semen extract (Table 1). DA-9701, Corydalis tuber
extract, and Pharbitidis semen extract at 200μg/mL showed
negligible inhibition on CYP1A2-mediated phenacetin O-
deethylation, CYP2A6-mediated coumarin 7-hydroxylation,
CYP2C8-mediated amodiaquine N-deethylation, CYP2C9-
mediated diclofenac 4-hydroxylation, CYP2C19-mediated
[S]-mephenytoin 4 -hydroxylation, and CYP3A-mediated
midazolam 1 -hydroxylation. IC50 values of corydaline and
palmatine, the marker compounds of DA-9701 for CYP2D6-
catalyzed bufuralol 1 -hydroxylation activity were 23.8 [23]
and 49.3μg/mL (our unpublished data), respectively.
Although corydaline and palmatine inhibited CYP2D6
isozyme, they are not the major constituents causing the
inhibition of CYP2D6 activity, because their contents in DA-
9701(corydaline,0.85μg/mgandpalmatine,0.13μg/mgDA-
9701) and Corydalis tuber extract (corydaline, 1.12μg/mg
and palmatine, 0.18μg/mg Corydalis tuber extract) are very
low. Therefore, other constituents may contribute to the
inhibition of CYP2D6 activity by DA-9701 and Corydalis
tuber extract. Further studies are needed to explore how the
constituentsofthosecompoundscontributetotheinhibition
of human CYP2D6 isozyme. The inhibitory potencies of
DA-9701, Corydalis tuber extract, and Pharbitidis semen
extract were not signiﬁcantly aﬀected after a 30-min period
of preincubation with human liver microsomes in the
presence of NADPH (Table 1), suggesting that a mechanism-
based inhibitory component was not present in DA-9701,
Corydalis tuber extract, and Pharbitidis semen.
Volume per dose index (VDI) is deﬁned as the volume
in which one dose would be diluted to obtain the corre-
sponding IC50 concentration, as described by Strandell et al.
[24], to determine the potential for in vivo inhibition of
herbal preparations. If VDI value for a herbal preparation
approaches 4L, corresponding to human blood volume,
the potential enzyme interaction of herbal preparation with
pharmaceuticals should be further investigated [24]. Since
a recommended human dose for DA-9701 is 30mg, VDI
value of DA-9701 for inhibition of CYP2D6 activity was
1.16L/dose, suggesting that DA-9701 may not be a potent
CYP2D6 inhibitor.Evidence-Based Complementary and Alternative Medicine 5
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Figure 1: Representative Dixon plots for inhibitory eﬀects of (a) DA-9701, (b) Corydalis Tuber extract, and (c) quinidine on CYP2D6-
catalyzed bufuralol 1 -hydroxylation in pooled human liver microsomes, H161. Each symbol represents the bufuralol concentration: 0.5μM
(∇), 1.0μM(  ), 2.0μM( ), and 5.0μM( ). Each data point represents the mean of triplicate experiments.
Table 3: Eﬀects of DA-9701, Corydalis tuber extract, and Pharbitidis semen extract on UGT metabolic activity in pooled human liver
microsomes, H161.
UGT Marker enzyme IC50 (μg/mL)
DA-9701 Corydalis tuber extract Pharbitidis semen extract
UGT1A1 Etoposide glucuronidation 188 290 No inhibition∗
UGT1A4 Triﬂuoperazine N-glucuronidation No inhibition No inhibition No inhibition
UGT1A9 Propofol glucuronidation No inhibition No inhibition No inhibition
UGT2B7 Azidothymidine glucuronidation No inhibition No inhibition No inhibition
∗Therewasnoinhibitionat200μg/mLofDA-9701,Corydalistuberextract,andPharbitidissemenextract.Thedatarepresenttheaverageofduplicateanalysis.6 Evidence-Based Complementary and Alternative Medicine
In an inhibition study, the apparent Ki value is a better
parameter for deﬁning the interaction of the inhibitor with
ap a r t i c u l a re n z y m e .Ki values and inhibition types (com-
petitive, noncompetitive, uncompetitive, or mixed) for DA-
9701 and Corydalis tuber extract were initially estimated by
graphical methods such as Lineweaver-Burk plot and Dixon
plot, but they were ultimately determined by nonlinear least-
square regression analysis for the best enzyme inhibition
model using Enzyme kinetics software. DA-9701 showed
noncompetitive inhibition for CYP2D6-catalyzed bufuralol
1 -hydroxylation, with a Ki value of 6.3μg/mL (Table 2,
Figure 1). Corydalis tuber extract competitively inhibited
CYP2D6-catalyzed bufuralol 1 -hydroxylation, with a Ki
value of 3.7μg/mL (Table 2, Figure 1). The inhibitory poten-
tialofcorydalineonCYP2D6activity(Ki valueof10.1μg/mL
(27.3μM)) [23] was not found to be strong, as compared
with the inhibition produced by quinidine [Ki value of
12ng/mL (0.038μM)], a selective inhibitor of CYP2D6
[25, 26].
We also evaluated the inhibitory potential of DA-9701,
Corydalis tuber extract, and Pharbitidis semen extract on
four major UGT isoform activities. DA-9701 and Cory-
dalis tuber extract inhibited UGT1A1-mediated etopo-
side glucuronidation, with IC50 values of 188 and 290μg/
mL, respectively. UGT1A4-mediated triﬂuoperazine N-
glucuronidation, UGT1A9-mediated propofol glucuronida-
tion, and UGT2B7-mediated azidothymidine glucuronida-
tion were not inhibited by treatment with DA-9701 and
Corydalis tuber extract (Table 3). Pharbitidis semen extract
showed no inhibition of UGT1A1, UGT1A4, UGT1A9, and
UGT2B7 activities in human liver microsomes (Table 3).
VDI value of DA-9701 for inhibition of UGT1A1 activity
was 0.16 L/dose, suggesting that DA-9701 may not inhibit in
vivoUGT1A1activity.Thiswassupportedbythecomparison
with IC50 values of UGT1A1 inhibitors, such as ritonavir
(IC50 = 1.7μM) and ketoconazole (IC50 = 7.3μM) [27].
CYP2D6 catalyzes oxidation of a wide range of sub-
strates,includingdesipramine,dextromethorphan,haloperi-
dol, S-metoprolol, nortryptyline, paroxetine, and tamoxifen
(http://medicine.iupui.edu/clinpharm/ddis/). Compared to
quinidine,aknowninhibitorofCYP2D6-catalyzedbufuralol
1 -hydroxylation [25, 26, 28], DA-9701 is a weak inhibitor
(Ki, 12ng/mL versus 6.3μg/mL). On the basis of an IC50
value and VDI value of 1.16 L for a 30mg dose, DA-9701
will be expected to have weak, if any, inhibition of CYP2D6-
catalyzed metabolism in vivo. However, no pharmacokinetic
data on DA-9701 are available. False prediction of in vivo
drug-drug interactions from in vitro data may be occurred
as a result of mechanism-based inhibition, plasma protein
binding of inhibitors, production of inhibitory metabolites,
and/or hepatic uptake. Therefore, the results need to be
conﬁrmed in clinical studies.
4. Conclusions
In conclusion, the eﬀects of DA-9701 and its component
herbs, Corydalis tuber extract and Pharbitidis semen extract,
on seven CYPs and four UGTs were evaluated across a wide
range of substrates using human liver microsomes in vitro.
Pharbitidis semen extract showed no inhibition of seven
CYPs and four UGTs in human liver microsomes. CYP2D6
activity was moderately inhibited by DA-9701 and Corydalis
tuber extract during incubation with NADPH in human
liver microsomes. On the basis of a Ki value and VDI value,
DA-9701 will be expected to have weak, if any, inhibition
of CYP2D6-catalyzed metabolism in vivo. Those results
suggest that high uptake of botanical drug DA-9701 or
Corydalis tuber extract may cause an interaction with drugs
metabolized by CYP2D6 in some individuals. It is important
to note, however, that the inhibition of CYP activities in
vitro does not necessarily translate into drug interactions in
clinical situations. Clinical trials to evaluate the inhibitory
eﬀects of DA-9701 on CYP2D6 remain to be conducted.
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